Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables: 2024

Historic Receivables for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2024 value amounting to $9.4 million.

  • ARS Pharmaceuticals' Receivables rose 4302.16% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.5 million, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Receivables of $9.4 million as of FY2024.
  • In the past 5 years, ARS Pharmaceuticals' Receivables registered a high of $9.4 million during FY2024, and its lowest value of $9.4 million during FY2024.
  • In the last 1 years, ARS Pharmaceuticals' Receivables had a median value of $9.4 million in 2024 and averaged $9.4 million.